AUROPHARMA Aurobindo Pharma Q3 FY26 results (Oct–Dec 2025) and concall
Aurobindo Pharma reported a strong Q3 FY26 with consolidated revenue growing 8.4% YoY and EBITDA margin at 20.5%. Growth was driven by robust performance in Europe and US injectables, alongside the Pen-G facility achieving break-even. The company is progressing on its biosimilar strategy and expects the Lannett acquisition to close in early Q1 FY27, while addressing procedural observations from the Eugia III inspection.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q3 FY26: revenue up 8.4%, net profit up 7.6% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 7,796 | 7,979 | 8,382 | 7,868 | 8,286 +6% | 8,646 +8% |
| EBITDA | 1,566 | 1,578 | 1,760 | 1,603 | 1,678 +7% | 1,773 +12% |
| Net profit | 817 | 846 | 903 | 824 | 848 +4% | 910 +8% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
